Covid Vaccine Race

An England study shows the Pfizer-BioNTech and AstraZeneca vaccines remain effective in reducing symptomatic disease risk.

The Food and Drug Administration (FDA) is expected to expand the Emergency Use Authorization (EUA) of the Pfizer-BioNTech and Moderna vaccines for a third dose in those who might be vulnerable to COVID-19.

The vaccine demonstrated an acceptable safety profile in the adolescent population.

The federal agency recommends that all women who are pregnant, recently pregnant, and planning to become pregnant get the COVID-19 vaccine.

Emergency authorization may be complete before the end of August, ensuring more protection for patients burdened with certain chronic diseases.

Findings also showed that women had a lower risk of testing positive than men.

With the US federal government health agencies discussing plans for a booster dose for Americans and WHO’s call for a moratorium on these shots, a tale of two vaccine strategies is emerging.

The report of promising phase 2 findings align with word that an FDA submission will be delayed until later this year.

What risks and benefits need to be considered with the return of in-person classes?

As the international world struggles to get first doses, the World Health Organization Director General Tedros Adhanom Ghebreyesus says this should also include high-risk populations.

A report says the timetable is for Labor Day or sooner.

A study looked at the efficacy of the Pfizer-BioNTech mRNA COVID-19 vaccine in a high-risk national population within a real-world setting.

Ownership language showed an additional boost in appointment and vaccination rates.

The study found that ¾ of the cases occurred in fully vaccinated individuals.

Reasons given for not vaccinating were safety issues and low risk for infection.

A conversation with Anna Legreid Dopp, Pharm. D.

With new mask guidance comes questions and confusion, especially with the new strain of COVID-19 and those who have been vaccinated.

Last influenza season was notably quiet during peaking COVID-19 cases. Experts explain what may influence risk of dueling epidemics this year.

With its latest earnings report showing the financial impact of the vaccine, the Delta variant becoming the dominant strain in the US, and concerns of waning immunity, the company believes there is evidence for an additional booster shot.

Public information campaigns may potentially boost rates of vaccination.

Asymptomatic and symptomatic COVID-19 cases among health care personnel were reduced after vaccination despite surge in infected patients.

Pfizer and Moderna will include children aged 5-11 years old in ongoing trials to speak toward risk of rare adverse events observed in other young recipients.

The statement includes over 50 societies and organizations, representing millions of workers.

While a significantly reduced effectiveness was seen with 1 dose, only a small reduction was observed after 2.

Impaired resilience was found to be associated with loneliness.

The designation moves the companies' PDUFA date up to January 2022, when BNT162b2 may become the first regulated COVID-19 vaccine.

The Johnson & Johnson vaccine showed neutralizing antibody responses against variants of concern.

Before other states adopt randomly-selected payouts for COVID-19 vaccine administration, further research is needed into these lotteries’ effects on potential increases in vaccination rates.

Those taking methotrexate had lower seroconversion rates compared to controls.

A meeting between developers and federal experts was inconclusive to the necessity of a third mRNA dose for COVID-19.